Amarin (AMRN +1%) gets a boost from some positive commentary out of Leerink Swann today, saying...


Amarin (AMRN +1%) gets a boost from some positive commentary out of Leerink Swann today, saying that Vascepa's prescription data appears to be tracking well. The firm notes that the largest TRx advance since the drug's launch was recorded last week, and the number of new prescriptions and refills are growing. Looking forward, Leerink thinks the AMRN's ramped-up marketing efforts and moves to obtain Tier 2 reimbursement should further accelerate TRx growth.

From other sites
Comments (1)
  • ralphey
    , contributor
    Comments (381) | Send Message
     
    Exactly what I am seeing in my practice !
    1 Apr 2013, 01:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs